Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tetraphase Pharmaceuticals has closed the second tranche of its $25 million series A financing to support the advancement of several novel and potent antibiotic drug candidates.
Subscribe to our email newsletter
This second tranche of $15 million was funded by existing investors – Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.
Guy Macdonald, president and CEO of Tetraphase, said: “Since our inception, we have made significant progress, applying our unique technology to the development of several novel and potent antibiotic drug candidates. We are very pleased that our investors share our enthusiasm for and confidence in our programs.”